Rockwell Medical to Release Fourth Quarter and Full-Year 2024 Results on Thursday, March 20, 2025
Rockwell Medical (Nasdaq: RMTI), a healthcare company focused on hemodialysis products, has scheduled its Q4 and full-year 2024 financial results release for Thursday, March 20, 2025. The company will issue a press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET.
The earnings call will feature presentations from key executives including President and CEO Mark Strobeck, Ph.D., CFO Jesse Neri, and Chief Commercial Officer Tim Chole. The discussion will cover financial and operational results, followed by a Q&A session.
Rockwell Medical (Nasdaq: RMTI), un'azienda sanitaria focalizzata sui prodotti per emodialisi, ha programmato il rilascio dei risultati finanziari del Q4 e dell'intero anno 2024 per giovedì 20 marzo 2025. L'azienda pubblicherà un comunicato stampa alle 6:00 ora orientale, seguito da una conferenza telefonica e una webcast in diretta alle 8:00 ora orientale.
La chiamata sugli utili presenterà interventi di dirigenti chiave tra cui il Presidente e CEO Mark Strobeck, Ph.D., il CFO Jesse Neri e il Chief Commercial Officer Tim Chole. La discussione coprirà i risultati finanziari e operativi, seguita da una sessione di domande e risposte.
Rockwell Medical (Nasdaq: RMTI), una empresa de atención médica centrada en productos de hemodiálisis, ha programado la publicación de sus resultados financieros del Q4 y del año completo 2024 para el jueves 20 de marzo de 2025. La empresa emitirá un comunicado de prensa a las 6:00 a.m. ET, seguido de una llamada de conferencia en vivo y una transmisión web a las 8:00 a.m. ET.
La llamada de ganancias contará con presentaciones de ejecutivos clave, incluyendo al Presidente y CEO Mark Strobeck, Ph.D., al CFO Jesse Neri y al Chief Commercial Officer Tim Chole. La discusión cubrirá los resultados financieros y operativos, seguida de una sesión de preguntas y respuestas.
록웰 메디컬 (Nasdaq: RMTI), 혈액 투석 제품에 중점을 둔 헬스케어 회사는 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 20일 목요일로 예정하고 있습니다. 회사는 동부 표준시 기준 오전 6시에 보도 자료를 발표한 후, 오전 8시에 실시간 전화 회의 및 웹캐스트를 진행할 예정입니다.
수익 전화 회의에서는 사장 겸 CEO인 Mark Strobeck 박사, CFO Jesse Neri, 상업 담당 최고 책임자 Tim Chole 등 주요 경영진의 발표가 있을 것입니다. 논의는 재무 및 운영 결과를 다룬 후 질의응답 세션이 이어질 것입니다.
Rockwell Medical (Nasdaq: RMTI), une entreprise de santé spécialisée dans les produits d'hémodialyse, a programmé la publication de ses résultats financiers du Q4 et de l'année complète 2024 pour jeudi 20 mars 2025. L'entreprise publiera un communiqué de presse à 6h00 HE, suivi d'une conférence téléphonique en direct et d'un webinaire à 8h00 HE.
La conférence des résultats comportera des présentations de dirigeants clés, notamment le président et PDG Mark Strobeck, Ph.D., le CFO Jesse Neri et le directeur commercial Tim Chole. La discussion portera sur les résultats financiers et opérationnels, suivie d'une session de questions-réponses.
Rockwell Medical (Nasdaq: RMTI), ein Gesundheitsunternehmen, das sich auf Produkte zur Hämodialyse spezialisiert hat, hat die Veröffentlichung seiner finanziellen Ergebnisse für Q4 und das gesamte Jahr 2024 auf Donnerstag, den 20. März 2025 terminiert. Das Unternehmen wird um 6:00 Uhr ET eine Pressemitteilung herausgeben, gefolgt von einer Live-Konferenzschaltung und Webcast um 8:00 Uhr ET.
Die Gewinnbesprechung wird Präsentationen von wichtigen Führungskräften, darunter Präsident und CEO Mark Strobeck, Ph.D., CFO Jesse Neri und Chief Commercial Officer Tim Chole, beinhalten. Die Diskussion wird die finanziellen und operativen Ergebnisse abdecken, gefolgt von einer Frage- und Antwortsitzung.
- None.
- None.
CONFERENCE CALL AND WEBCAST DETAILS
Date: Thursday, March 20, 2025
Time: 8:00am ET
Live Number: (888) 660-6347 // (International) 1 (929) 201-6594
Conference Call ID: 4944610
Webcast and Replay: www.RockwellMed.com/Results
Speakers:
- Mark Strobeck, Ph.D. — President and Chief Executive Officer; and
- Jesse Neri — SVP, Chief Financial Officer
- Tim Chole — SVP, Chief Commercial Officer
Format: Discussion of fourth quarter and full-year 2024 financial and operational results followed by Q&A.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023 and 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.rockwellmed.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220524550/en/
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@RockwellMed.com
Source: Rockwell Medical
FAQ
When will Rockwell Medical (RMTI) release its Q4 2024 earnings?
How can investors access RMTI's Q4 2024 earnings call?
Who will be speaking at Rockwell Medical's Q4 2024 earnings call?
What will be discussed during RMTI's March 20, 2025 earnings call?
